Don’t miss your opportunity to be a part of this event, now a highly anticipated Campbell tradition, a decade in the making! More information at: library.campbell.edu/symposium
Sign up or log in to bookmark your favorites and sync them to your phone or calendar.
Oxidative stress plays a crucial role in Alzheimer’s disease (AD) pathology. This study explores the potential of targeting the Keap1-Nrf2 pathway as a therapeutic approach. Keap1 negatively regulates Nrf2, a key antioxidant defense mechanism. Using molecular modeling and virtual screening, we identified and modified compounds such as Andrographolide, Farrerol, and Curcumin analogs to enhance their binding affinity to Keap1. By disrupting Keap1-Nrf2 interaction, these compounds could activate Nrf2, reducing oxidative damage and neuroinflammation. Our findings highlight promising drug candidates for AD treatment, with improved binding affinity and potential blood-brain barrier penetration.
